# US 2016/0250341 A1 · Designed repeat proteins binding to serum albumin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250341 A1
- Document ID: US20160250341A1
- Status: Published application
- Kind: A1
- Application number: 15/013,092
- Filed: 2016-02-02
- Published: 2016-09-01
- Earliest claimed: 2010-11-26
- Assignees: Molecular Partners AG
- Applicants: Molecular Partners AG
- Inventors: Daniel STEINER; Hans Kaspar BINZ; Maya GULOTTI-GEORGIEVA; Frieder W. MERZ; Douglas PHILLIPS; Ivo SONDEREGGER
- Web page: https://patentgrep.com/patent/US20160250341A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 35/00: Antineoplastic agents
- C07K 14/001: {by chemical synthesis}
- C07K 14/47: from mammals
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of increasing the terminal plasma half-life of a bioactive compound in a mammal, comprising covalently attaching a binding protein to said bioactive compound, wherein said binding protein comprises at least one ankyrin repeat domain, wherein said ankyrin repeat domain has binding specificity for a mammalian serum albumin, and wherein said covalent attachment of said binding protein increases the terminal plasma half-life of said bioactive compound at least 2-fold as compared to the terminal plasma half-life of said unmodified bioactive compound.

### Claim 18 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an ankyrin repeat module having an amino acid sequence selected from the group consisting of:
(1) SEQ ID NO:49;
(2) SEQ ID NO:50;
(3) SEQ ID NO:51;
(4) SEQ ID NO:52;
(5) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 49 exchanged by any amino acid and having the ankyrin repeat sequence motif
(SEQ ID NO: 53)
X1DX2X3X4X5TPLHLAAX6X7GHLX8IVEVLLKX9GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of A, D, M, F, S, I, T, N, Y, and K;
X2 represents an amino acid residue selected from the group consisting of E, K, D, F, M, N, I and Y;
X3 represents an amino acid residue selected from the group consisting of W, R, N, T, H, K, A and F;
X4 represents an amino acid residue selected from the group consisting of G and S;
X5 represents an amino acid residue selected from the group consisting of N, T and H;
X6 represents an amino acid residue selected from the group consisting of N, V and R;
X7 represents an amino acid residue selected from the group consisting of E, Y, N, D, H,
S, A, Q, T and G;
X8 represent an amino acid residue selected from the group consisting of E and K;
X9 represent an amino acid residue selected from the group consisting of S, A, Y, H and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:53 are exchanged by any amino acid;
(6) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 51 exchanged by any amino acid and having the ankyrin repeat sequence motif
(SEQ ID NO: 10)
X1DX2X3GX4TPLHLAAX5X6GHLEIVEVLLKX7GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of A, D, M, F, S, I, T, N, Y and K;
X2 represents an amino acid residue selected from the group consisting of E, K, D, F, M, N, I and Y;
X3 represents an amino acid residue selected from the group consisting of W, R, N, T, H, K, A and F;
X4 represents an amino acid residue selected from the group consisting of N, T and H;
X5 represents an amino acid residue selected from the group consisting of N, V and R;
X6 represents an amino acid residue selected from the group consisting of E, Y, N, D, H, S, A, Q, T and G;
X7 represent an amino acid residue selected from the group consisting of S, A, Y, H and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:10 are exchanged by any amino acid;
(7) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 49 exchanged by any amino acid and having the ankyrin repeat sequence motif
(SEQ ID NO: 11)
X1DYFX2HTPLHLAARX3X4HLX5IVEVLLKX6GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of D, K and A;
X2 represents an amino acid residue selected from the group consisting of D, G and S;
X3 represents an amino acid residue selected from the group consisting of E, N, D, H, S, A, Q, T and G;
X4 represents an amino acid residue selected from the group consisting of G and D;
X5 represents an amino acid residue selected from the group consisting of E, K and G;
X6 represents an amino acid residue selected from the group consisting of H, Y, A and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:11 are exchanged by any amino acid;
(8) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 50 exchanged by any amino acid and having the ankyrin repeat sequence motif
(SEQ ID NO: 54)
X1DFX2GX3TPLHLAAX4X5GHLEIVEVLLKX6GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of F, S, L and K;
X2 represents an amino acid residue selected from the group consisting of V and A;
X3 represents an amino acid residue selected from the group consisting of R and K;
X4 represents an amino acid residue selected from the group consisting of S and N;
X5 represents an amino acid residue selected from the group consisting N, D, Q, S, A, T and E;
X6 represents an amino acid residue selected from the group consisting of A, H, Y, S and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:54 are exchanged by any amino acid;
(9) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 50 exchanged by any amino acid and has the ankyrin repeat sequence motif
(SEQ ID NO: 12)
X1DFX2GX3TPLHLAAX4DGHLEIVEVLLKX5GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of F, S, L and K;
X2 represents an amino acid residue selected from the group consisting of V and A;
X3 represents an amino acid residue selected from the group consisting of R and K;
X4 represents an amino acid residue selected from the group consisting of S and N;
X5 represents an amino acid residue selected from the group consisting of A, H, Y, S and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:12 are exchanged by any amino acid;
(10) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 51 exchanged by any amino acid and has the ankyrin repeat sequence motif
(SEQ ID NO: 13)
X1DX2X3GTTPLHLAAVYGHLEX4VEVLLKX5GADVNA
wherein
X1 represents an amino acid residue selected from the group consisting of K, A, D, M, F, S, I, T, N, and Y;
X2 represents an amino acid residue selected from the group consisting of E, K, D, F, M, N and Y;
X3 represents an amino acid residue selected from the group consisting of R, N, T, H, K, A and F;
X4 represents an amino acid residue selected from the group consisting of I and M;
X5 represents an amino acid residue selected from the group consisting of H, Y, K, A and N; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:13 are exchanged by any amino acid; and
(11) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 52 exchanged by any amino acid and has the ankyrin repeat sequence motif
(SEQ ID NO: 14)
X1NETGYTPLHLADSSGHX2EIVEVLLKX3X4X5DX6NA
wherein
X1 represents an amino acid residue selected from the group consisting of Q and K;
X2 represents an amino acid residue selected from the group consisting of L and P;
X3 represents an amino acid residue selected from the group consisting of H, N, Y and A;
X4 represents an amino acid residue selected from the group consisting of G and S;
X5 represents an amino acid residue selected from the group consisting of A, V, T and S;
X6 represents an amino acid residue selected from the group consisting of V and F; and
wherein optionally up to 5 amino acids in other than in positions denoted with X in SEQ ID NO:14 are exchanged by any amino acid.

### Claim 19 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an amino acid sequence that has at least 85% amino acid sequence identity with one ankyrin repeat domain selected from the group consisting of SEQ ID NOs: 17 to 31 and 43 to 48, wherein G at position 1 and/or S at position 2 of said ankyrin repeat domain are optionally missing.

### Claim 20 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an ankyrin repeat module having an amino acid sequence selected from the group consisting of:
(1) SEQ ID NO:49;
(2) SEQ ID NO:50;
(3) SEQ ID NO:51;
(4) SEQ ID NO:52;
(5) an amino acid sequence with up to 5 amino acids in SEQ ID NO: 49 exchanged by any amino acid;
(6) an amino acid sequence with up to 4 amino acids in SEQ ID NO: 50 exchanged by any amino acid;
(7) an amino acid sequence with up to 3 amino acids in SEQ ID NO: 51 exchanged by any amino acid; and
(8) an amino acid sequence with up to 6 amino acids in SEQ ID NO: 52 exchanged by any amino acid.

### Claim 21 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an ankyrin repeat module having an amino acid sequence with up to 5 amino acids in SEQ ID NO: 49 exchanged by any amino acid.

### Claim 22 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the bioactive compound in mice is increased to about 2 to 2.5 days.

### Claim 23 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the bioactive compound in cynomolgus monkeys is increased to about 10 to 15 days.

### Claim 24 (depends on 1)

The method of claim 1, wherein the bioactive compound is a proteinaceous bioactive compound.

### Claim 25 (depends on 8)

The method of claim 8, wherein the proteinaceous bioactive compound is (1) a binding domain having binding specificity for a target different from mammalian serum albumin, (2) a cytokine, (3) a growth factor, (4) an antibody or a fragment thereof, or (5) a hormone.

### Claim 26 (depends on 1)

The method of claim 1, wherein the bioactive compound is a non-proteinaceous bioactive compound.

### Claim 27 (depends on 10)

The method of claim 10, wherein the non-proteinaceous bioactive compound is a toxin, a small molecule targeting GPCRs, or an antibiotic.

### Claim 28 (depends on 1)

The method of claim 1, wherein said covalent attachment of said binding protein increases the terminal plasma half-life of the bioactive compound at least 5-fold as compared to the terminal plasma half-life of said unmodified bioactive compound.

### Claim 29 (depends on 1)

The method of claim 1, wherein said covalent attachment of said binding protein increases the terminal plasma half-life of the bioactive compound at least 10-fold as compared to the terminal plasma half-life of said unmodified bioactive compound.

### Claim 30 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the binding protein in human is at least 5 days.

### Claim 31 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the binding protein in human is at least 10 days.

### Claim 32 (depends on 1)

A method of claim 1, wherein said binding protein has an at least 5-fold higher terminal plasma half-life in a mammal compared to a corresponding binding protein not binding to a mammalian serum albumin.

### Claim 33 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the bioactive compound in human is increased to at least 5 days.

### Claim 34 (depends on 1)

The method of claim 1, wherein the terminal plasma half-life of the bioactive compound in human is increased to at least 10 days.

### Claim 35 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an ankyrin repeat module having an amino acid sequence with up to 3 amino acids in SEQ ID NO: 49 exchanged by any amino acid.

### Claim 36 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises an ankyrin repeat module having the amino acid sequence of SEQ ID NO: 49.

### Claim 37 (depends on 1)

The method of claim 1, wherein said ankyrin repeat domain comprises a first ankyrin repeat module having an amino acid sequence with up to 5 amino acids in SEQ ID NO: 49 exchanged by any amino acid and a second ankyrin repeat module having an amino acid sequence with up to 4 amino acids in SEQ ID NO: 50 exchanged by any amino acid, wherein said first ankyrin repeat module is N-terminal of said second ankyrin repeat module.
